国产创新药领域重磅合作频出，这笔60亿美元BD大单花落AI制药领域

每日经济新闻08-06

每经记者｜许立波每经编辑｜董兴生8月5日，晶泰科技（02228.HK，证券名称：晶泰控股）宣布与DoveTree完成总订单规模约470亿港元（59.9亿美元）的管线合作签约，并已收到协议约定的首付款约4亿港元（5100万美元）。此次合作创下人工智能（AI）+机器人新药研发领域订单规模的新纪录。受此消息影响，8月6日，晶泰科技股价收涨12.42%，市值接近300亿港元。根据协议条款，晶泰科技...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

HOOK虎克
08-07
HOOK虎克

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2557435308?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-06 22:12","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2557435308","market":"hk","top_or_hot":-1,"title":"国产创新药领域重磅合作频出，这笔60亿美元BD大单花落AI制药领域","media":"每日经济新闻","content":"<div>\n<p>每经记者｜许立波    每经编辑｜董兴生8月5日，晶泰科技（02228.HK，证券名称：晶泰控股）宣布与DoveTree完成总订单规模约470亿港元（59.9亿美元）的管线合作签约，并已收到协议约定的首付款约4亿港元（5100万美元）。此次合作创下人工智能（AI）+机器人新药研发领域订单规模的新纪录。受此消息影响，8月6日，晶泰科技股价收涨12.42%，市值接近300亿港元。根据协议条款，晶泰科技...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806221321973799a9&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>国产创新药领域重磅合作频出，这笔60亿美元BD大单花落AI制药领域</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n国产创新药领域重磅合作频出，这笔60亿美元BD大单花落AI制药领域\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-06 22:12 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806221321973799a9&s=b><strong>每日经济新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>每经记者｜许立波    每经编辑｜董兴生8月5日，晶泰科技（02228.HK，证券名称：晶泰控股）宣布与DoveTree完成总订单规模约470亿港元（59.9亿美元）的管线合作签约，并已收到协议约定的首付款约4亿港元（5100万美元）。此次合作创下人工智能（AI）+机器人新药研发领域订单规模的新纪录。受此消息影响，8月6日，晶泰科技股价收涨12.42%，市值接近300亿港元。根据协议条款，晶泰科技...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806221321973799a9&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B543WZ88.USD","symbol_name":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806221321973799a9&s=b","article_id":"2557435308","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806221321973799a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2557435308","pubTimestamp":1754489566,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"此次合作创下人工智能+机器人新药研发领域订单规模的新纪录。受此消息影响，8月6日，晶泰科技股价收涨12.42%，市值接近300亿港元。AI制药从“技术验证期”迈入“价值兑现期”2023年以来，全球AI制药领域的交易数量和规模呈爆发式增长，单笔交易额普遍在数亿美元至十亿美元以上。通过此次战略合作，石药集团总计将获得超过50亿美元的潜在交易金额。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","01477":"欧康维视生物-B","IE0008368742.USD":"首域中国增长基金I Acc","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","BK1161":"生物科技","BK1191":"制药","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","01093":"石药集团","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","06978":"永泰生物-B","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","BK1515":"抗疫概念","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","BK1574":"生物医药B类股","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","BK1521":"挪威政府全球养老基金持仓","LU0140636845.USD":"施罗德大中华区股票A Acc","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC"},"translate_title":"Heavy cooperation in the field of domestic innovative drugs is frequent, and this US $6 billion BD order goes to the field of AI pharmaceuticals","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":0.9,"01477":1,"06978":1},"content_text":"每经记者｜许立波    每经编辑｜董兴生8月5日，晶泰科技（02228.HK，证券名称：晶泰控股）宣布与DoveTree完成总订单规模约470亿港元（59.9亿美元）的管线合作签约，并已收到协议约定的首付款约4亿港元（5100万美元）。此次合作创下人工智能（AI）+机器人新药研发领域订单规模的新纪录。受此消息影响，8月6日，晶泰科技股价收涨12.42%，市值接近300亿港元。根据协议条款，晶泰科技与DoveTree就多款处于临床前阶段的大分子及小分子创新药资产达成合作，并将针对一系列DoveTree指定的靶点进行新药研发，DoveTree独家享有相关药物全球范围的独家开发和商业化权利。作为回报，除首付款外，晶泰科技还有权获得约3.85亿港元（4900万美元）的进一步付款，以及金额达约462亿港元（58.9亿美元）的潜在里程碑付款及销售分成。券商分析称首付款金额高于预期晶泰科技是一个基于量子物理，以人工智能赋能和机器人驱动的创新型研发平台。DoveTree是一家创新生物制药公司，由生物制药界传奇企业家Gregory Verdine博士创立。根据晶泰科技方面提供给《每日经济新闻》记者的资料，此次合作中，双方将深度融合Verdine团队顶尖的生物学机制研究、靶点选择和商业化开发能力，与晶泰科技AI驱动的药物研发技术优势，两家企业形成高度优势互补，共同推进肿瘤学、免疫及炎症疾病、神经系统疾病及代谢失调领域的高潜力管线项目。Verdine表示，AI已成为攻克具有研发挑战性的创新靶点的关键技术。晶泰科技方面称，双方还计划在未来共同推进对由DoveTree选定的一系列针对极具挑战性或高价值靶点的新药研发项目，具体方案在进一步商议中。东吴证券在最新研报中点评称，晶泰科技为全球AI for Science稀缺标的，此次合作对于公司是里程碑事件，首付款金额高于预期，证明了晶泰科技的人工智能+机器人技术在药物发现领域的价值。同时，其商业模式已初具雏形，为未来商业化订单落地打下坚实基础，未来中短期收入有望迎来快速增长。AI制药从“技术验证期”迈入“价值兑现期”2023年以来，全球AI制药领域的交易数量和规模呈爆发式增长，单笔交易额普遍在数亿美元至十亿美元以上。据记者不完全梳理，仅2024年下半年，就有诺华与Generate达成超过10亿美元的生成式AI合作协议；吉利德与Genesis Therapeutics签署多靶点小分子开发协议，首付款达3500万美元；礼来与Genetic Leap达成基因疗法药物开发合作，交易总额最高4.09亿美元。而在中国，锐格医药、英硅智能、晶泰科技等企业也纷纷与跨国药企达成合作。今年6月13日，石药集团（01093.HK）宣布，公司已与知名跨国药企阿斯利康订立战略研发合作协议，将利用公司的AI引擎双轮驱动的高效药物发现平台，发现和开发新型口服小分子候选药物。通过此次战略合作，石药集团总计将获得超过50亿美元的潜在交易金额。随着行业发展，AI制药企业在产业链中的角色定位也正在发生重大转变。埃格林医药联合创始人、首席医学官李长青曾对《每日经济新闻》记者分析称，过去，AI制药企业往往仅作为CRO或工具平台，在项目中承担“服务提供者”的定位。但如今，越来越多AI制药企业正在成为药物临床研发的主导者，尤其在ADC（抗体药物偶联物）等前沿赛道中，已经开始具备“主动创造高价值资产”的能力。“其次则是商业模式的转变。”李长青表示，以前AI制药企业多为一次性收费，“拿一笔就完了”。而现在，行业正逐步转向以“首付款+里程碑+销售分成”为特征的共创共赢机制，来实现风险的共担以及利益的长期分享。而且，这些变化并非局限于个别企业，而是代表整个AI制药产业正经历从“技术验证期”迈入“价值兑现期”的结构性转型。头豹研究院医疗行业高级分析师何婉怡也对记者表达了类似的观点。其认为，国内AI制药企业正从“技术服务提供者”升级为“全球研发主角”，通过技术平台与管线资产的协同，在BD（商务拓展）谈判中占据主动。何婉怡也强调，随着行业从“技术验证”迈向“商业化落地”，AI制药的BD交易将不仅是金额的比拼，更是技术深度、管线差异性和全球资源整合能力的综合较量。封面图片来源：视觉中国-VCG41N1446647763","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":464964978323944,"gmtCreate":1754541676043,"gmtModify":1754541676884,"author":{"id":"3546893915367433","authorId":"3546893915367433","name":"HOOK虎克","avatar":"https://static.tigerbbs.com/1b6e123f82746952c11c82c7ceaf2cc7","vip":1,"crmLevel":9,"crmLevelSwitch":0,"idStr":"3546893915367433","authorIdStr":"3546893915367433"},"htmlText":"&nbsp; &nbsp;&nbsp;","listText":"&nbsp; &nbsp;&nbsp;","text":"","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/464964978323944","repostId":2557435308,"repostType":2,"repost":{"id":"2557435308","kind":"news","pubTimestamp":1754489566,"share":"https://www.laohu8.com/m/news/2557435308?lang=&edition=full","pubTime":"2025-08-06 22:12","market":"hk","language":"zh","title":"国产创新药领域重磅合作频出，这笔60亿美元BD大单花落AI制药领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2557435308","media":"每日经济新闻","summary":"此次合作创下人工智能+机器人新药研发领域订单规模的新纪录。受此消息影响，8月6日，晶泰科技股价收涨12.42%，市值接近300亿港元。AI制药从“技术验证期”迈入“价值兑现期”2023年以来，全球AI制药领域的交易数量和规模呈爆发式增长，单笔交易额普遍在数亿美元至十亿美元以上。通过此次战略合作，石药集团总计将获得超过50亿美元的潜在交易金额。","content":"<div>\n<p>每经记者｜许立波    每经编辑｜董兴生8月5日，晶泰科技（02228.HK，证券名称：晶泰控股）宣布与DoveTree完成总订单规模约470亿港元（59.9亿美元）的管线合作签约，并已收到协议约定的首付款约4亿港元（5100万美元）。此次合作创下人工智能（AI）+机器人新药研发领域订单规模的新纪录。受此消息影响，8月6日，晶泰科技股价收涨12.42%，市值接近300亿港元。根据协议条款，晶泰科技...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806221321973799a9&s=b\">Web Link</a>\n\n</div>\n","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>国产创新药领域重磅合作频出，这笔60亿美元BD大单花落AI制药领域</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n国产创新药领域重磅合作频出，这笔60亿美元BD大单花落AI制药领域\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-06 22:12 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806221321973799a9&s=b><strong>每日经济新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>每经记者｜许立波    每经编辑｜董兴生8月5日，晶泰科技（02228.HK，证券名称：晶泰控股）宣布与DoveTree完成总订单规模约470亿港元（59.9亿美元）的管线合作签约，并已收到协议约定的首付款约4亿港元（5100万美元）。此次合作创下人工智能（AI）+机器人新药研发领域订单规模的新纪录。受此消息影响，8月6日，晶泰科技股价收涨12.42%，市值接近300亿港元。根据协议条款，晶泰科技...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806221321973799a9&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","01477":"欧康维视生物-B","IE0008368742.USD":"首域中国增长基金I Acc","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","BK1161":"生物科技","BK1191":"制药","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","01093":"石药集团","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","06978":"永泰生物-B","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","BK1515":"抗疫概念","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","BK1574":"生物医药B类股","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","BK1521":"挪威政府全球养老基金持仓","LU0140636845.USD":"施罗德大中华区股票A Acc","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806221321973799a9&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2557435308","content_text":"每经记者｜许立波    每经编辑｜董兴生8月5日，晶泰科技（02228.HK，证券名称：晶泰控股）宣布与DoveTree完成总订单规模约470亿港元（59.9亿美元）的管线合作签约，并已收到协议约定的首付款约4亿港元（5100万美元）。此次合作创下人工智能（AI）+机器人新药研发领域订单规模的新纪录。受此消息影响，8月6日，晶泰科技股价收涨12.42%，市值接近300亿港元。根据协议条款，晶泰科技与DoveTree就多款处于临床前阶段的大分子及小分子创新药资产达成合作，并将针对一系列DoveTree指定的靶点进行新药研发，DoveTree独家享有相关药物全球范围的独家开发和商业化权利。作为回报，除首付款外，晶泰科技还有权获得约3.85亿港元（4900万美元）的进一步付款，以及金额达约462亿港元（58.9亿美元）的潜在里程碑付款及销售分成。券商分析称首付款金额高于预期晶泰科技是一个基于量子物理，以人工智能赋能和机器人驱动的创新型研发平台。DoveTree是一家创新生物制药公司，由生物制药界传奇企业家Gregory Verdine博士创立。根据晶泰科技方面提供给《每日经济新闻》记者的资料，此次合作中，双方将深度融合Verdine团队顶尖的生物学机制研究、靶点选择和商业化开发能力，与晶泰科技AI驱动的药物研发技术优势，两家企业形成高度优势互补，共同推进肿瘤学、免疫及炎症疾病、神经系统疾病及代谢失调领域的高潜力管线项目。Verdine表示，AI已成为攻克具有研发挑战性的创新靶点的关键技术。晶泰科技方面称，双方还计划在未来共同推进对由DoveTree选定的一系列针对极具挑战性或高价值靶点的新药研发项目，具体方案在进一步商议中。东吴证券在最新研报中点评称，晶泰科技为全球AI for Science稀缺标的，此次合作对于公司是里程碑事件，首付款金额高于预期，证明了晶泰科技的人工智能+机器人技术在药物发现领域的价值。同时，其商业模式已初具雏形，为未来商业化订单落地打下坚实基础，未来中短期收入有望迎来快速增长。AI制药从“技术验证期”迈入“价值兑现期”2023年以来，全球AI制药领域的交易数量和规模呈爆发式增长，单笔交易额普遍在数亿美元至十亿美元以上。据记者不完全梳理，仅2024年下半年，就有诺华与Generate达成超过10亿美元的生成式AI合作协议；吉利德与Genesis Therapeutics签署多靶点小分子开发协议，首付款达3500万美元；礼来与Genetic Leap达成基因疗法药物开发合作，交易总额最高4.09亿美元。而在中国，锐格医药、英硅智能、晶泰科技等企业也纷纷与跨国药企达成合作。今年6月13日，石药集团（01093.HK）宣布，公司已与知名跨国药企阿斯利康订立战略研发合作协议，将利用公司的AI引擎双轮驱动的高效药物发现平台，发现和开发新型口服小分子候选药物。通过此次战略合作，石药集团总计将获得超过50亿美元的潜在交易金额。随着行业发展，AI制药企业在产业链中的角色定位也正在发生重大转变。埃格林医药联合创始人、首席医学官李长青曾对《每日经济新闻》记者分析称，过去，AI制药企业往往仅作为CRO或工具平台，在项目中承担“服务提供者”的定位。但如今，越来越多AI制药企业正在成为药物临床研发的主导者，尤其在ADC（抗体药物偶联物）等前沿赛道中，已经开始具备“主动创造高价值资产”的能力。“其次则是商业模式的转变。”李长青表示，以前AI制药企业多为一次性收费，“拿一笔就完了”。而现在，行业正逐步转向以“首付款+里程碑+销售分成”为特征的共创共赢机制，来实现风险的共担以及利益的长期分享。而且，这些变化并非局限于个别企业，而是代表整个AI制药产业正经历从“技术验证期”迈入“价值兑现期”的结构性转型。头豹研究院医疗行业高级分析师何婉怡也对记者表达了类似的观点。其认为，国内AI制药企业正从“技术服务提供者”升级为“全球研发主角”，通过技术平台与管线资产的协同，在BD（商务拓展）谈判中占据主动。何婉怡也强调，随着行业从“技术验证”迈向“商业化落地”，AI制药的BD交易将不仅是金额的比拼，更是技术深度、管线差异性和全球资源整合能力的综合较量。封面图片来源：视觉中国-VCG41N1446647763","news_type":1,"symbols_score_info":{"01093":0.9,"01477":1,"06978":1}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.3","shortVersion":"4.35.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2557435308","isCrawlerRequest":true}